Company Overview of Bird Rock Bio, Inc.
Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of novel immune-inflammatory regulators. It offers novel biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis, and nonalcoholic steatohepatitis. The company’s technology enables the company to leverage biologic therapeutic specificity across a set of targets from a family of proteins, the G-protein coupled receptor (GPCR) protein family, where specificity in binding is important. It develops novel antibodies with upsized potential that represent antibody therapeutics to GPCR targets validated with small molecules; and antibody therapeutics to validated targets for ...
505 Coast Boulevard
La Jolla, CA 92037
Founded in 2006
Key Executives for Bird Rock Bio, Inc.
Chief Executive Officer, President and Director
Senior Vice President of Research & Development, Bology & Pharmacology
Vice President of Business Development
Vice President of Translational Research
Compensation as of Fiscal Year 2016.
Bird Rock Bio, Inc. Key Developments
Bird Rock Bio Announces Positive Results from Two Clinical Studies
Mar 16 16
Bird Rock Bio, Inc. announced positive results from two clinical studies assessing the safety and harmacokinetics of gerilimzumab, a novel anti-IL-6 cytokine antibody for the treatment of inflammatory diseases, including rheumatoid arthritis (RA). In both studies, gerilimzumab demonstrated safety as well as pharmacokinetic support for very low (less than 50 mg per patient, per year) and infrequent (one subcutaneous injection every eight weeks) dosing, which is anticipated to enable an extremely low annual price as low as $2,000 per patient.Â Bird Rock Bio plans to complete submission for a pivotal trial for RA by the first half of this year. The two clinical studies in healthy adult volunteers focused on the pharmacokinetics of gerilimzumab in single and multiple ascending doses respectively to validate its pharmacology and potential pharmacoeconomic profile. In the single ascending dose study, gerilimzumab was administered by subcutaneous injection at four dosages (1 mg, 5 mg, 15 mg, and 30 mg) and in the multiple ascending dose study, gerilimzumab was administered by subcutaneous injection at two dosages (5 mg and 20 mg) once per month for three months. A total of 50 subjects were included in both studies, which also assessed the safety and tolerability of gerilimzumab compared with placebo. In both studies, gerilimzumab was well tolerated, and no serious adverse events were reported. The average half-life of gerilimzumab observed in the two studies was approximately 50 days, supporting a proposed dosing regimen of 5 mg to 10 mg once every eight weeks. Compared with biologics for RA such as Roche's Actemra or Abbvie's Humira, this represents 1/10th to 1/100th the amount of drug product. Â With this data, gerilimzumab presents the opportunity for a dramatically reduced price for therapy while offering patients much greater convenience with just six doses per year.
RuiYi Doses First Patient in Double-Blinded Trial of Gerilimzumab to Treat Arthritis
Sep 23 15
RuiYi has dosed first patient with Gerilimzumab novel monoclonal antibody to treat rheumatoid arthritis (RA) and other autoimmune disorders. Gerilimzumab is directed against the IL-6 cytokine. The double-blinded and placebo controlled trial includes single and multiple ascending dose cohorts. RuiYi plans to release the trial's results in the first quarter of 2015 and advance Gerilimzumab into further studies, including in moderate to severe RA.
RuiYi Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:30 AM
Sep 3 15
RuiYi Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:30 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 25, 2016